Goldman Sachs Has Buy On Hologic (HOLX)

Goldman Sachs has a Buy rating and a $25 price target on shares of Hologic, Inc. HOLX.

In a note to investors, Goldman writes, "We are adding shares of Buy-rated Hologic to the Americas Conviction list, with 25% upside to our unchanged 6-month price target of $25. We believe the market underappreciates HOLX’s new product cycle in tomosynthesis, which represents a major advance in breast cancer detection. In our view, investors should own HOLX now that FDA approval has been granted, thus de-risking a key regulatory overhang and paving the way for a series of positive catalysts over the next 6 – 9 months that we think will drive shares in advance of significant commercial uptake. Lastly, we believe HOLX’s 12% FCF yield (2x the group average) provides valuation support."

Shares of HOLX lost 2 cents yesterday to close at $19.98, a loss of 0.1%.